IDH2 and central nervous system cancer: Similarly, when we assessed GPR133 expression as a function of ATRX status, there was no difference within the core of IDH mutant gliomas with preserved (oligodendrogliomas) or lost (astrocytomas) ATRX (Figure 4Ci).